Evidence map›Paper›PMID 38886043›Full record

ArticleJournal of clinical pathology2025

Clinicopathological significance and prognostic analysis of p21 and EGFR in colorectal cancer: a retrospective analysis on 12 319 cases in China.

Yang Fei, Mengke Ma, Lu Gan, Midie Xu, Yu Yang, Dan Huang, Weiqi Sheng

Abstract read
In one paragraph

Article in Journal of clinical pathology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yang Fei *Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China.ORCID http://orcid.org/0009-0009-0188-3427
Mengke Ma *Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China.
Lu Gan *Department of Medical Oncology, Zhongshan Hospital, Fudan University, Shanghai, China.
Midie XuDepartment of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China.
Yu YangDepartment of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China.
Dan HuangDepartment of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China.
Weiqi ShengDepartment of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China shengweiqi2006@163.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsColorectal cancer (CRC) is the third most common malignancy worldwide. Accurate pathological diagnosis and predictive abilities for treatment response and prognosis are crucial for patients with CRC. This study aims to analyse the expressions of p21 and EGFR in CRC and their relationships with clinicopathological characteristics and prognosis to enhance diagnostic and prognostic evaluations.

methodsThis study conducted a retrospective analysis of p21 and EGFR expressions in 12 319 Chinese patients with CRC using immunohistochemistry. The relationships between these expressions and clinicopathological characteristics and survival outcomes were explored through statistical and survival analyses.

resultsDifferential expressions of p21 and EGFR in CRC were closely related to clinicopathological characteristics and significantly impacted overall survival (OS). p21 expression was associated with the primary tumour site, mucinous subtype, lymphovascular invasion, perineural invasion, circumferential resection margin, T stage, N stage, tumour, node, metastases (TNM) stage, and mismatch repair status. EGFR expression was related to mucinous subtype, tumour differentiation, lymphovascular invasion, perineural invasion, tumour size, T stage, N stage, TNM stage and

conclusionp21 and EGFR serve as potential indicators for pathological diagnosis, risk stratification, and predicting treatment efficacy and prognosis in patients with CRC. The study's findings provide valuable references for personalised treatment and prognosis evaluation in clinical practice.

Indexed as

Biomarkers, TumorColorectal NeoplasmsCyclin-Dependent Kinase Inhibitor p21ErbB ReceptorsAdultAgedAged, 80 and overChinaFemaleHumansImmunohistochemistryMaleMiddle AgedNeoplasm StagingNomogramsPrognosisBiomarkers, TumorCDKN1A protein, humanCyclin-Dependent Kinase Inhibitor p21EGFR protein, humanErbB ReceptorsCOLORECTAL CANCERColorectal NeoplasmsEGFRPathology, Surgical

Identifiers

PMID38886043
PMCPMC12505112

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.